Shanghai Securities News China Securities Network News (reporter Confucius Ziyuan) Hengrui Pharmaceutical announced that the company received the "Drug Registration Certificate" approved and issued by the State Food and Drug Administration. Proline hengliflozin tablets obtain a certificate of drug registration. The approved indications are "This product is suitable for improving blood glucose control in adults with type 2 diabetes; Darcily isethione isethionate tablets obtain a drug registration certificate." The approved indications are "This product combined with fulvestrant for the treatment of recurrent or metastatic breast cancer that is positive for hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2)-negative after endocrine therapy." "Darcily is a class 1 new chemical drug independently developed by Hengrui Pharmaceutical, which is an oral, efficient and selective small molecule CDK4/6 inhibitor.
The company announced on the same day that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received the "Drug Registration Certificate" approved and issued by the State Food and Drug Administration. Ambroxol hydrochloride oral solution obtained the drug registration certificate. The drug can increase the secretion of serous glands of the respiratory mucosa and reduce the secretion of mucus glands, thereby reducing the viscosity of sputum, while promoting the secretion of pulmonary surfactants, increasing the movement of bronchial cilia to make sputum easy to cough out, suitable for acute and chronic bronchitis caused by sputum viscous, sputum cough difficulties.
![These vitamins, eye drops, and pediatric cough syrup were written off! Come and see if your house has it?[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)